Leramistat is under clinical development by Istesso and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Leramistat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Leramistat overview
MBS-2320 is under development for the treatment of rheumatoid arthritis, and autoimmune disorders. It is administered through oral route. It is a new molecular entity
It was under development for the treatment of colitis, multiple myeloma.
Istesso overview
Istesso is a biotech company that specializes in the discovery and development of drugs for chronic diseases. Istesso’s lead investigational drug is leramistat, a first-in-class programmed disease-resolving drug. It also offers MBS2687, IST003, IST005 and IST004 for autoimmune, neuroprotection and fibrosis diseases. The company’s products treats a wide range of diseases, including bone erosive inflammatory indications, autoimmune diseases, fibrotic diseases, neurological diseases, and malignancies. Istesso is headquartered in Kings Cross, London, United Kingdom.
For a complete picture of Leramistat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
